Powered by
ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART
Mar 7, 2017 - Thomson Reuters ONE

ObsEva SA / ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

- IMPLANT2 study to confirm efficacy and safety of novel, oral oxytocin receptor antagonist in infertile patients undergoing embryo transfer as part of assisted reproductive technology (ART) -

Geneva, Switzerland - 07 March 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical com

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox